# Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

> **NCT04312594** · PHASE2 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 91 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Jaktinib Hydrochloride Tablets
- **DRUG:** Jaktinib Hydrochloride Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04312594
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-08
- **Primary completion:** 2022-06-09
- **Final completion:** 2022-06-09
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04312594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04312594, "Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04312594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*